By this definition, PPHM’s claims with respect to FoB’s are essentially meaningless, IMO.
Maybe not, Dew. It appears PPHM is expanding Avid's capacity a lot, perhaps in anticipation of several, if not many, biotech companies electing to get into the biosimilar business and needing a reliable manufacturer of their products. My opinion only and I'm only speculating. Also, even if I'm right, the anticipated demand may not materialize. That's another reason why I'm invested in PPHM and you're not.
:-)
Market Data 
Markets 
AI
